FTC chief calls for a ban on generic pay-for-delay deals

In the wake of an FTC report that so-called “authorized generics” lower prices, commission chairman Jon Leibowitz says Congress should pass pending legislation to ban or restrict a related mechanism known as pay-for-delay arrangements in which a branded drug company pays potential generic competitors to stay out of the market.

In a speech to the Center for American Progress, Leibowitz said eliminating such agreements could save $35 billion in healthcare costs over 10 years.

“From my perspective, … the decision about whether to restrict pay-for-delay settlements should be simple,” Leibowitz declared. “On the one hand you have savings to American consumers of $35 billion or more over 10 years, about $12 billion of which would be savings to the federal government, and the prospect of helping to pay for healthcare reform as well as the ability to set a clear national standard to stop anti-competitive conduct. On the other hand, you have a permissive legal regime that allows competitors to make collusive deals on the backs of consumers.”
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.